UFP Technologies Inc. | Small-cap | Healthcare
$219.56
0.08%
| UFP Technologies Stock Comparison:
UFP Technologies vs Abbott LaboratoriesUFP Technologies vs Boston ScientificUFP Technologies vs QuidelOrthoUFP Technologies vs EnovisUFP Technologies vs ConmedUFP Technologies vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 151.2M
Gross Profit 43.5M 28.80%
Operating Income 24.9M 16.45%
Net Income 17.2M 11.36%
EPS (Diluted) $2.21

Balance Sheet Metrics

Total Assets 642.6M
Total Liabilities 282.0M
Shareholders Equity 360.7M
Debt to Equity 0.78

Cash Flow Metrics

Operating Cash Flow 14.8M
Free Cash Flow 11.0M

Revenue & Profitability Trend

UFP Technologies Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i504.4M400.1M353.8M206.3M179.4M
Cost of Goods Sold i357.7M287.8M263.5M155.2M134.7M
Gross Profit i146.7M112.2M90.3M51.1M44.7M
Gross Margin % i29.1%28.1%25.5%24.8%24.9%
Operating Expenses
Research & Development i-----
Selling, General & Administrative i62.2M50.9M45.8M29.5M27.5M
Other Operating Expenses i-----
Total Operating Expenses i62.2M50.9M45.8M29.5M27.5M
Operating Income i84.5M61.3M44.5M21.6M17.2M
Operating Margin % i16.7%15.3%12.6%10.5%9.6%
Non-Operating Items
Interest Income i---49.0K0
Interest Expense i8.1M3.6M2.8M39.0K83.0K
Other Non-Operating Income-3.4M-3.8M11.0M-390.0K-825.0K
Pre-tax Income i73.0M53.9M52.7M21.2M16.3M
Income Tax i14.0M9.0M10.9M5.3M2.9M
Effective Tax Rate % i19.2%16.7%20.7%25.1%17.9%
Net Income i59.0M44.9M41.8M15.9M13.4M
Net Margin % i11.7%11.2%11.8%7.7%7.5%
Key Metrics
EBITDA i99.4M72.6M56.4M30.1M25.1M
EPS (Basic) i$7.69$5.89$5.52$2.11$1.79
EPS (Diluted) i$7.58$5.83$5.45$2.09$1.77
Basic Shares Outstanding i76680007624000756400075240007484000
Diluted Shares Outstanding i76680007624000756400075240007484000

Income Statement Trend

UFP Technologies Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i13.4M5.3M4.5M11.1M24.2M
Short-term Investments i-----
Accounts Receivable i84.7M64.4M55.1M39.4M26.4M
Inventory i87.5M70.2M53.5M33.4M18.6M
Other Current Assets-----
Total Current Assets i194.9M144.6M116.3M87.3M71.9M
Non-Current Assets
Property, Plant & Equipment i16.1M13.6M13.2M9.3M2.2M
Goodwill i523.6M290.6M294.4M283.4M123.4M
Intangible Assets i144.3M64.1M68.4M67.6M19.7M
Long-term Investments-----
Other Non-Current Assets6.6M6.4M9.2M5.4M3.9M
Total Non-Current Assets i434.0M259.5M261.8M246.8M131.3M
Total Assets i629.0M404.1M378.2M334.1M203.2M
Liabilities
Current Liabilities
Accounts Payable i24.3M22.3M20.0M10.6M4.1M
Short-term Debt i16.7M7.2M6.5M6.2M1.2M
Current Portion of Long-term Debt-----
Other Current Liabilities--6.9M4.7M-
Total Current Liabilities i76.3M58.2M56.0M38.8M15.1M
Non-Current Liabilities
Long-term Debt i189.3M38.8M61.9M78.1M1.0M
Deferred Tax Liabilities i3.3M428.0K448.0K3.3M5.1M
Other Non-Current Liabilities6.2M7.1M8.7M15.2M1.3M
Total Non-Current Liabilities i209.9M59.8M84.7M100.9M11.2M
Total Liabilities i286.2M118.0M140.6M139.7M26.3M
Equity
Common Stock i77.0K76.0K76.0K75.0K75.0K
Retained Earnings i306.5M247.5M202.6M160.8M144.9M
Treasury Stock i587.0K587.0K587.0K587.0K587.0K
Other Equity-----
Total Shareholders Equity i342.8M286.1M237.5M194.4M176.9M
Key Metrics
Total Debt i206.0M46.0M68.4M84.4M2.2M
Working Capital i118.6M86.4M60.4M48.5M56.7M

Balance Sheet Composition

UFP Technologies Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i59.0M44.9M41.8M15.9M13.4M
Depreciation & Amortization i14.7M11.4M11.9M8.4M8.3M
Stock-Based Compensation i6.8M4.6M3.2M2.4M1.8M
Working Capital Changes i-15.9M-23.2M-32.2M-11.1M1.8M
Operating Cash Flow i66.9M42.1M29.8M13.9M25.4M
Investing Activities
Capital Expenditures i-9.6M-10.5M21.9M-5.3M-4.3M
Acquisitions i-197.5M0-20.7M-96.2M0
Investment Purchases i-----
Investment Sales i-----
Investing Cash Flow i-207.1M-10.5M1.3M-101.5M-4.3M
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i284.2M0040.0M0
Debt Repayment i-126.9M-32.1M-64.1M-29.0K-5.5M
Financing Cash Flow i152.2M-30.7M-26.3M73.9M-6.3M
Free Cash Flow i56.9M30.8M4.0M8.9M20.7M
Net Change in Cash i12.0M906.0K4.8M-13.7M14.9M

Cash Flow Trend

UFP Technologies Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 25.19
Forward P/E 25.34
Price to Book 4.35
Price to Sales 2.85
PEG Ratio 0.97

Profitability Ratios

Profit Margin 11.40%
Operating Margin 16.45%
Return on Equity 19.29%
Return on Assets 11.53%

Financial Health

Current Ratio 2.77
Debt to Equity 46.98
Beta 1.14

Per Share Data

EPS (TTM) $8.63
Book Value per Share $49.99
Revenue per Share $76.58

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
ufpt1.7B25.194.3519.29%11.40%46.98
Abbott Laboratories 229.3B16.534.5330.93%32.43%26.50
Boston Scientific 153.7B61.766.8511.55%13.55%53.09
QuidelOrtho 1.8B-0.860.64-15.64%-17.01%100.33
Enovis 1.7B-2.040.66-28.25%-37.80%56.75
Conmed 1.7B15.401.6811.69%8.31%87.93

Financial data is updated regularly. All figures are in the company's reporting currency.